Tuesday, February 17, 2026 2/17/2026

Supplement to U01CA260469

Award Number: U01CA260469
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/22/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

Supplement to U01CA260469 - Project Summary African Americans develop and die from SARS-CoV-2 infection more than any other racial group in the United States, including in majority African American cities such as Flint, Michigan. SARS-CoV-2 disparities stem from many interconnected causes. Yet, connections to inflammatory biological processes in COVID-19 disparities remain largely unknown. Evaluating inflammatory responses can be facilitated by SARS-CoV-2 antibody testing, which can be used to identify and compare inflammation among those with and without confirmed SARS-CoV-2 infection, and to conduct cross-race comparisons of inflammatory factors. However, African Americans will be reluctant to partake in conventional antibody testing programs due to medical mistrust and experiences with racism that are salient in the COVID-19 era. There is thus an urgent need to develop and deploy culturally-relevant communication and antibody testing programs. Our long-term goal is to identify and reduce unjust COVID-19 racial disparities. The immediate objective is to better encourage understanding and uptake of SARS-CoV-2 antibody testing. The central hypothesis is that African-Americans will be receptive to antibody testing when benefits and limitations are communicated in a culturally effective manner, and when non-invasive salivary collection methods and assays are used. Our rationale is that combining culturally effective health communication with salivary testing will reduce mistrust and promote uptake that can lead to better grasping the role of inflammation in COVID-19 disparities. Our aims are to 1) develop and compare effects of a general versus culturally-targeted video about antibody testing on African American and White Flint residents’ antibody testing attitudes and uptake; 2) identify and compare effects of a general versus culturally- targeted video on activation of medical mistrust and racism-related cognition among African Americans when considering antibody testing; 3) measure and identify multi-analyte inflammatory biomarker profiles among Flint Registry enrollees who complete salivary antibody testing and compare inflammatory biomarker profiles by race and antibody status. In collaboration with clinical and community partners, we will prepare and evaluate general and culturally-targeted video tutorials about SARS-CoV-2 antibody testing. These brief videos will be distributed to the Flint community through the Flint Registry – a highly visible local health resource exchange. In collaboration with leading salivary bioscience experts, we will furnish an opportunity to engage in at-home salivary antibody screening – a non-invasive route to antibody testing that is highly suited to disparities- oriented COVID-19 research. The proposed research is innovative and significant in highlighting that culturally- targeted communication and non-invasive antibody testing are vital to propelling disparities-oriented inflammatory COVID-19 research. Knowledge to be gained includes video tutorials and insights about community-facing salivary collection that can be immediately disseminated across SeroNet to better promote including racial monitories in ongoing studies of inflammation and antibody testing.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$1,096 )
2026	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 360	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	000	2	1/12/2026	SUPPLEMENT FOR EXPANSION	-$1,096
														Subtotal = -$1,096

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	002	2	3/26/2025	SUPPLEMENT FOR EXPANSION	$0
2025	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	005	2	4/7/2025	SUPPLEMENT FOR EXPANSION	$0
2025	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	004	2	4/7/2025	SUPPLEMENT FOR EXPANSION	$0
2025	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	001	2	3/26/2025	SUPPLEMENT FOR EXPANSION	$0
2025	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	000	2	3/26/2025	TERMINATION	$0
2025	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	003	2	4/7/2025	OTHER REVISION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $295,988 )
2024	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	002	2	8/16/2024	SUPPLEMENT FOR EXPANSION	$295,988
2024	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	001	2	8/16/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	000	2	8/16/2024	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $295,988

Issue Date FY: 2023 ( Subtotal = $964,759 )
2023	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	004	2	8/25/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	000	2	6/2/2023	SUPPLEMENT FOR EXPANSION	$964,759
2023	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	002	2	6/21/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	001	2	6/21/2023	EXTENSION WITH OR WITHOUT FUNDS	$0
2023	2020	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	003	1	7/26/2023	NEW	$0
														Subtotal = $964,759

Issue Date FY: 2022 ( Subtotal = $630,937 )
2022	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	002	2	9/22/2022	EXTENSION WITH OR WITHOUT FUNDS	$630,937
2022	2020	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	001	1	2/14/2022	NEW	$0
2022	2020	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	000	1	12/20/2021	NEW	$0
														Subtotal = $630,937

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	000	1	10/30/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $1,326,405 )
2020	2020	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	000	1	9/22/2020	NEW	$1,326,405
														Subtotal = $1,326,405

Grand Total All Awards = $3,216,993

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Supplement to U01CA260469

Award Number: U01CA260469

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/22/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer